Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
89bio, Inc. announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis with fibrosis...
DREAMM-8 results for Blenrep in multiple myeloma featured in a late-breaking presentation and ASCO's Press Programme Updated results from a supported...
The designation was supported by data from the double-blind, placebo-controlled phase 2b AHFIRM trial.
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line